American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 901-903, December 2007

Should Reducing Nocturnal Blood Pressure Be a Therapeutic Target in CKD? The Time Is Ripe for a Clinical Outcomes Trial

  • Mahboob Rahman, MD, MS

      Affiliations

    • Division of Nephrology and Hypertension, Case Western Reserve University, University Hospitals of Cleveland, Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, Ohio
    • Corresponding Author InformationAddress correspondence to Mahboob Rahman, MD, MS, 11100 Euclid Avenue, Cleveland, OH 44106.
    • ,
  • Lawrence J. Appel, MD

      Affiliations

    • Welch Center for Prevention, Epidemiology and Clinical Research, Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Article Outline

 

Related article, p. 908

Ambulatory blood pressure (ABP) monitoring is a noninvasive technique in which blood pressure (BP) is recorded over an extended period of time, typically 24 hours or more, outside of the office setting. As such, it provides information on diurnal BP patterns, which cannot be obtained from either clinic or home measurements. In the general population without chronic kidney disease (CKD), use of ambulatory BP monitoring has been proposed as a means to identify persons with white-coat hypertension, that is, persons at lower risk of cardiovascular disease than suggested by clinic measurements. The opposite might be true for CKD patients. Because of the high prevalence of abnormal diurnal BP patterns in CKD patients, clinic BP may underestimate the risk of cardiovascular disease, as well as the risk of progression of kidney disease. Hence, the likely role of ABP in CKD patients is to identify patients at higher “cardiovascular-kidney risk.”

The normal diurnal pattern of BP is a reduction in nighttime BP of 10% or more compared to daytime BP levels (persons with this pattern are termed “dippers”). Elevated nocturnal BP and an abnormal dipping status are extremely common in patients with CKD.1, 2, 3 One of the earliest studies was by Portaluppi et al who compared age-matched hypertensive patients with and without CKD.2 Mean 24-hour BP was similar in the 2 groups, but those without CKD had a nocturnal systolic pressure BP reduction of 12.7 mm Hg, while those with CKD showed an average increase of 2.7 mm Hg. This lack of decline in nocturnal BP has been confirmed in several other studies.4, 5, 6 In the African American Study of Kidney Disease and Hypertension (AASK), as many as 40% of African American patients with hypertensive CKD had a reversed diurnal pattern, that is, higher nocturnal BP than daytime BP.7

The pathophysiologic mechanisms underlying elevation of BP at night remain uncertain. Activation of the sympathetic nervous system,2, 8 altered sodium balance requiring a higher pressure at night to achieve adequate natriuresis,9 elevated renin and aldosterone levels,10 and decreased endothelial-derived vasodilators have been postulated. High nocturnal BP has also been associated with sleep apnea11 and insulin resistance.12

Although the etiology is uncertain, both abnormal dipping status (nondippers compared to dippers) and higher nighttime BP are associated with greater BP-related target organ damage and higher cardiovascular morbidity and mortality.13, 14 Several cross-sectional studies have shown that high nocturnal BP is associated with proteinuria.15, 16, 17 In prospective studies, elevated nocturnal BP or nondipping BP is associated with incident proteinuria in diabetics,18 more rapid decline in glomerular filtration rate in hypertensive patients with CKD,19 and loss of function in renal allografts.20 In a prospective study of CKD patients, a 1–standard deviation increase in nocturnal systolic BP was associated with a more than 2-fold increase in end-stage renal disease and a 50% higher risk of death. Even in patients with relatively preserved renal function, glomerular filtration rate remained stable among dippers (mean change, 1.3%) but declined among nondippers (mean change, −15.9%) during a median follow-up period of 3.2 years.21

To date, few studies have tested strategies designed to lower nocturnal BP and restore normal diurnal pattern. In hypertensive patients without CKD, use of diuretics22 and shifting the time of medication (valsartan23 and diltiazem24) administration to the evening have been shown to reduce nocturnal BP. In the setting of CKD, 1 study documented that administration of the calcium channel blocker isradipine in the evening lowered nocturnal BP.25

In view of the paucity of available data, the study by Minutolo et al in this issue of AJKD is an important advance. This pre-post, single-arm study addressed the issue of whether shifting the time of drug administration from morning to evening can safely and effectively restore normal circadian pattern in patients with an estimated glomerular filtration rate less than 90 mL/min/1.73 m2 (1.5 mL/s/1.73 m2), a nondipper BP profile (nighttime-to-daytime BP ratio of > 0.9), and controlled daytime BP (<135/85 mm Hg). At baseline, the pattern of antihypertensive medication use was typical of that used in CKD, that is, most patients were on combination therapy. Importantly, the intervention was quite simple. Patients on monotherapy were asked to take their medications in the evening instead of the morning. For those on multiple medications, at least 1 of the medications was taken in the evening.

After 8 weeks, the vast majority of patients (88%) had converted from a nondipper to a dipper profile. Nocturnal BP was lowered by an average of 7 mm Hg without an increase in daytime BP; somewhat surprising is the observation that office BP was also lower after 8 weeks. Results were consistent regardless of the antihypertensive medication. This finding suggests the effective component of the intervention was medication timing rather than a specific drug effect. Of considerable interest is the finding that the intervention, albeit brief, just 8 weeks, reduced proteinuria. Interestingly, the extent of proteinuria reduction correlated with the night-day ratio, not the level of nocturnal BP. No adverse effects were reported.

Despite these intriguing results, the study has some limitations. The core design was a pre-post study without a control arm. Hence, whether the BP changes reflect habituation to the measurement technique is unclear. The patient population was small, just 32 patients, and was a convenience sample of patients referred for ambulatory blood pressure monitoring. It does not reflect the broad spectrum of the CKD patients; for example, only 17% of patients had diabetes. The intervention lasted only 8 weeks; whether the effects persist or diminish over time is unknown. The study tested only 1 intervention. Alternate approaches to lowering nocturnal BP, such as addition of a small dose of an antihypertensive agent in the evening, might likewise be effective. Finally, the racial/ethnic composition of this Italian cohort certainly differs from that of other countries, particularly the United States, where CKD disproportionately affects African Americans. In view of these limitations, replication in other patient populations is warranted.

This paper provides useful, preliminary data to guide the design of a clinical outcome trial. The simple maneuver of switching the time of drug administration from morning to evening appears to safely lower nocturnal BP and restore a normal diurnal BP pattern. The next logical question is whether lowering nocturnal BP can retard the progression of CKD and prevent cardiovascular complications. This is particularly important in the context of recent data which document that hypertensive CKD continues to progress in the setting of recommended BP therapy (an office BP goal of < 130/80 mm Hg and provision of renin-angiotensin-system blocking medication).26 Such findings highlight the urgent need to develop and test novel interventions that retard the progression of CKD. The time is now ripe for a clinical outcomes trial of therapy that lowers nocturnal BP.

Back to Article Outline

Acknowledgements 

Support: None.

Financial Disclosure: Dr Rahman reports that his institution received research support grants from King Pharmaceuticals and Astra-Zeneca; Dr Appel reports having received research support from King Pharmaceuticals.

Back to Article Outline

References 

  1. Robles NR, Cancho B, Ruiz-Calero R, et al. Nighttime blood pressure fall in renal disease patients. Renal Fail. 2003;25:829–837
  2. Portaluppi F, Montanari L, Massari M, et al. Loss of nocturnal decline of blood pressure in hypertension due to chronic renal failure. Am J Hypertens. 1991;4:20–26
  3. Farmer CK, Goldsmith DJ, Cox J, et al. An investigation of the effect of advancing uraemia, renal replacement therapy and renal transplantation on blood pressure diurnal variability. Nephrol Dial Transplant. 1997;12:2301–2307
  4. Townsend RR, Ford V. Ambulatory blood pressure monitoring: coming of age in nephrology. J Am Soc Nephrol. 1996;7:2279–2287
  5. McGlothan KR, Wyatt RJ, Ault BH, et al. Predominance of nocturnal hypertension in pediatric renal allograft recipients. Pediatr Transplant. 2006;10:558–564
  6. Csiky B, Kovacs T, Wagner L, et al. Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Nephrol Dial Transplant. 1999;14:86–90
  7. Phillips RA, Appel LJ, Gabriel A, et al. Diurnal patterns of BP in African Americans with hypertensive kidney disease: Results from the AASK Cohort Study. Am J Hypertens. 2003;16:99A;(abstr)
  8. Portaluppi F, Montanari L, Ferlini M, et al. Altered circadian rhythms of blood pressure and heart rate in non-hemodialysis chronic renal failure. Chronobiol Int. 1990;7:321–327
  9. Sachdeva A, Weder AB. Nocturnal sodium excretion, blood pressure dipping, and sodium sensitivity. Hypertens. 2006;48:527–533
  10. Jensen LW, Pedersen EB. Nocturnal blood pressure and relation to vasoactive hormones and renal function in hypertension and chronic renal failure. Blood Press. 1997;6:332–342
  11. Portaluppi F, Provini F, Cortelli P, et al. Undiagnosed sleep-disordered breathing among male nondippers with essential hypertension. J Hypertens. 1997;15:1227–1233
  12. Davidson MB, Vidt DG, Hoogwerf BJ, et al. Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprotein cholesterol ratio in patients without diabetes mellitus. Am J Cardiol. 2005;95:123–126
  13. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–2415
  14. White WB. Ambulatory blood-pressure monitoring in clinical practice. N Engl J Med. 2003;348:2377–2378
  15. Opie LH, Muller FO, Myburgh DP, et al. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Am J Hypertens. 1997;10:250–260
  16. Bianchi S, Bigazzi R, Baldari G, et al. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens. 1994;7:23–29
  17. Paoletti E, Bellino D, Amidone M, et al. Relationship between arterial hypertension and renal damage in chronic kidney disease: insights from ABPM. J Nephrol. 2006;19:778–782
  18. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797–805
  19. Timio M, Venanzi S, Lolli S, et al. ”Non-dipper” hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol. 1995;43:382–387
  20. Wadei HM, Amer H, Taler SJ, et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index. J Am Soc Nephrol. 2007;18:1607–1615
  21. Davidson MB, Hix JK, Vidt DG, et al. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med. 2006;166:846–852
  22. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1999;100:1635–1638
  23. Hermida RC, Calvo C, Ayala DE, et al. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertens. 2005;46:960–968
  24. White WB, Lacourciere Y, Gana T, et al. Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. Am Heart J. 2004;148:628–634
  25. Portaluppi F, Vergnani L, Manfredini R, et al. Time-dependent effect of isradipine on the nocturnal hypertension in chronic renal failure. Am J Hypertens. 1995;8:719–726
  26. Appel L, Agodoa L, Bakris G, et al. Relentless progression of chronic kidney disease despite excellent blood pressure control and use of AEI inhibitor therapy; Results from the African American Study of Kidney Disease and Hypertension (AASK) Cohort Study. J Am Soc Nephrol. 2006;17:54

PII: S0272-6386(07)01358-3

doi:10.1053/j.ajkd.2007.10.005

Refers to article:

  • Changing the Timing of Antihypertensive Therapy to Reduce Nocturnal Blood Pressure in CKD: An 8-Week Uncontrolled Trial , 21 September 2007

    Roberto Minutolo, Francis B. Gabbai, Silvio Borrelli, Raffaele Scigliano, Paolo Trucillo, Diego Baldanza, Simona Laurino, Sara Mascia, Giuseppe Conte, Luca De Nicola
    American Journal of Kidney Diseases December 2007 (Vol. 50, Issue 6, Pages 908-917)

American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 901-903, December 2007

Article Tools